ACTRN12619001292167已完成4 期
The pharmacokinetics and safety of metformin in patients with liver disease
St Vincent's Hospital, Sydney0 个研究点目标入组 24 人开始时间: 2019年9月19日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Patients with chronic liver disease who are naïve to metformin treatment and do not have a diagnosis of type 2 diabetes mellitus.
排除标准
- •Significant renal impairment (eGFR < 30 mL/min), or women lactating, pregnant or of childbearing potential and unwilling to avoid becoming pregnant during the study.
研究者
相似试验
已完成
不适用
The safety and disposition of metformin in people with liver disease and diabetes already treated with metformiChronic liver diseaseMetabolic and Endocrine - DiabetesOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonDiabetesACTRN12619001348145St Vincent's Hospital, Sydney34
已完成
不适用
A study of factors affecting the concentrations of metformin in type 2 diabetic patientsType 2 diabetesMetabolic and Endocrine - DiabetesACTRN12611000908932Prof Richard Day120
招募中
4 期
Can metformin be safely used in patients with heart failure?Cardiovascular - Other cardiovascular diseasesChronic heart failureACTRN12617001418369St Vincent's Hospital Sydney50
终止
4 期
Can metformin be used safely in dialysis patients?Renal and Urogenital - Kidney diseaseType 2 diabetes mellitusEnd stage kidney disease.Metabolic and Endocrine - DiabetesACTRN12616000675426St Vincent's Hospital Sydney80
已完成
不适用
Pharmacokinetics and Pharmacodynamics of metformin in patients with type 2 diabetes and renal impairmentDiabetic NephropathyNL-OMON38577niversitair Medisch Centrum Groningen110